Barros-Miñones · Neuropharmacology 2015 · Controlled animal experiment · n=?

Contribution of dopamine to mitochondrial complex I inhibition and dopaminergic deficits caused by methylenedioxymethamphetamine in mice.

Cited 13 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Non-clinical animal research (CEBM Level 5)

PubMed 25666033 · doi:10.1016/j.neuropharm.2015.01.025 · record verified 2026-08-26

What was done

Researchers investigated the contribution of dopamine (DA) to MDMA-induced mitochondrial complex I inhibition and dopaminergic neurotoxicity in mice. They pharmacologically manipulated dopamine synthesis (using L-dopa and DA depletion), dopamine uptake (using the transporter blocker GBR 12909), and dopamine metabolism (using the monoamine oxidase inhibitor pargyline), testing both systemic and intrastriatal MDMA administration across brain regions (striatum and hippocampus).

What was found

Striatal mitochondrial complex I activity decreased 1 hour after MDMA administration, an effect absent in DA-depleted mice and in the dopamine-sparse hippocampus. L-dopa alone significantly reduced complex I activity and exacerbated dopaminergic deficits when combined with systemic MDMA, but caused no damage when combined with intrastriatal MDMA. Blocking dopamine uptake with GBR 12909 and inhibiting dopamine metabolism with pargyline both prevented acute complex I inhibition and long-term dopaminergic neurotoxicity. The abstract reports qualitative changes and directions without specific numerical values, percentages, or effect sizes.

Why it matters

These findings suggest that MDMA-induced dopaminergic neurotoxicity in mice depends on monoamine oxidase-mediated dopamine metabolism and peripheral MDMA metabolites rather than direct intrinsic toxicity of MDMA alone.

Limits

The abstract reports no exact sample sizes (n), quantitative values, or confidence intervals. The study was conducted entirely in mice, which are known to exhibit dopaminergic neurotoxicity from MDMA unlike primates and rats, where serotonergic toxicity typically predominates, limiting direct clinical translation.

Cited by